Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more
Cytogen Inc (217330) - Total Liabilities
Latest total liabilities as of September 2025: ₩26.02 Billion KRW
Based on the latest financial reports, Cytogen Inc (217330) has total liabilities worth ₩26.02 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cytogen Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Cytogen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cytogen Inc Competitors by Total Liabilities
The table below lists competitors of Cytogen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HYUNDAI BIOLAND Co.Ltd
KQ:052260
|
Korea | ₩27.91 Billion |
|
Development Advance Solution Co Ltd
KO:058730
|
Korea | ₩177.72 Billion |
|
GEA Grenobl. Elect.
PA:GEA
|
France | €16.51 Million |
|
Datagate Bilgisayar Malzemeleri Ticaret AS
IS:DGATE
|
Turkey | TL5.28 Billion |
|
Singha Estate Public Company Limited
BK:S
|
Thailand | ฿49.24 Billion |
|
ICBC Turkey Bank AS
IS:ICBCT
|
Turkey | TL93.98 Billion |
|
DAEMO Engineering Co. Ltd
KQ:317850
|
Korea | ₩17.24 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Cytogen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytogen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytogen Inc (2014–2024)
The table below shows the annual total liabilities of Cytogen Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩23.89 Billion | +13.27% |
| 2023-12-31 | ₩21.09 Billion | -40.69% |
| 2022-12-31 | ₩35.56 Billion | +9.36% |
| 2021-12-31 | ₩32.52 Billion | +226.05% |
| 2020-12-31 | ₩9.97 Billion | +455.30% |
| 2019-12-31 | ₩1.80 Billion | +152.43% |
| 2018-12-31 | ₩711.51 Million | -24.91% |
| 2017-12-31 | ₩947.50 Million | -79.34% |
| 2016-12-31 | ₩4.59 Billion | +187.30% |
| 2015-12-31 | ₩1.60 Billion | +1.68% |
| 2014-12-31 | ₩1.57 Billion | -- |